Nightfood Holdings Inc. (OTCQB: NGTF), operating through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio's OEB-5 sterile injectable cGMP facility. This deployment expands the initiative beyond Phase 1 materials logistics operations and into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation, and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce's LIM-E autonomous GMP support robot at the SAPU Bio facility, where the systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes, and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology, and life sciences environments, with PUR-E operating as part of TechForce's Robotics-as-a-Service Provider (RaaSP) platform. The deployment marks a critical step in addressing the stringent requirements of sterile manufacturing, including contamination control and precision in handling hazardous materials.
The implications of this announcement are significant for the pharmaceutical industry, which faces increasing pressure to improve efficiency and compliance while managing labor shortages. By integrating autonomous robots into clean rooms, TechForce Robotics aims to reduce human error, enhance consistency, and enable 24/7 operations in environments that require strict adherence to Good Manufacturing Practices (GMP). The collaboration with Oncotelic, a biopharmaceutical company focused on cancer therapeutics, underscores the potential for robotics to support the production of sterile injectable drugs, a segment with high demand and regulatory scrutiny.
Nightfood Holdings delivers its solutions through a Robotics-as-a-Service (RaaS) model, providing customers with flexible, scalable automation solutions while generating recurring revenue opportunities. As the Company expands into pharmaceutical automation, laboratory automation, industrial automation, and other high-precision applications, it continues to leverage strategic partnerships and advanced engineering capabilities to accelerate innovation and commercialization across multiple high-growth markets. The deployment at SAPU Bio positions TechForce Robotics as a key player in the convergence of robotics and pharmaceutical manufacturing, potentially setting a precedent for broader adoption in regulated environments.
For more details, the full press release is available at https://ibn.fm/mXU1p. The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF.
